JP2023535695A5 - - Google Patents
Info
- Publication number
- JP2023535695A5 JP2023535695A5 JP2023504023A JP2023504023A JP2023535695A5 JP 2023535695 A5 JP2023535695 A5 JP 2023535695A5 JP 2023504023 A JP2023504023 A JP 2023504023A JP 2023504023 A JP2023504023 A JP 2023504023A JP 2023535695 A5 JP2023535695 A5 JP 2023535695A5
- Authority
- JP
- Japan
- Prior art keywords
- coronavirus
- ace2
- substitution
- protein
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063053817P | 2020-07-20 | 2020-07-20 | |
| US63/053,817 | 2020-07-20 | ||
| US202163150686P | 2021-02-18 | 2021-02-18 | |
| US63/150,686 | 2021-02-18 | ||
| PCT/US2021/042372 WO2022020353A2 (en) | 2020-07-20 | 2021-07-20 | Methods and compositions for treatment and prevention of coronavirus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023535695A JP2023535695A (ja) | 2023-08-21 |
| JP2023535695A5 true JP2023535695A5 (cg-RX-API-DMAC7.html) | 2024-07-30 |
Family
ID=77301019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504023A Pending JP2023535695A (ja) | 2020-07-20 | 2021-07-20 | コロナウイルス感染症の治療及び予防のための方法及び組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230272359A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4182458A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023535695A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230058045A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116171324A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021312238A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3189732A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022020353A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021252164B2 (en) | 2020-04-09 | 2026-07-02 | Finncure Oy | Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses |
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
| CA3185230A1 (en) * | 2020-07-06 | 2022-01-13 | Shengjiang Liu | Catalysis deactivated angiotensin-converting enzyme 2 (ace2) variants and their uses |
| CA3257654A1 (en) * | 2022-04-13 | 2023-10-19 | Paradigm Immunotherapeutics, Inc. | METHODS OF PREVENTION OR TREATMENT OF RESPIRATORY VIRUS INFECTION, PARTICULARLY SARS-CoV-2 |
| CN119265271B (zh) * | 2024-12-09 | 2025-04-22 | 上海益诺思生物技术股份有限公司 | 一种评价ade效应的系统及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| DE3751873T2 (de) | 1986-04-09 | 1997-02-13 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US6174530B1 (en) | 1993-05-05 | 2001-01-16 | Gryphon Sciences | Homogeneous polyoxime compositions and their preparation by parallel assembly |
| US6184344B1 (en) | 1995-05-04 | 2001-02-06 | The Scripps Research Institute | Synthesis of proteins by native chemical ligation |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| US6989363B1 (en) * | 1997-12-11 | 2006-01-24 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor |
| WO2000070032A1 (en) * | 1999-05-13 | 2000-11-23 | Zymogenetics, Inc. | Zace2: a human metalloenzyme |
| US20040102369A1 (en) * | 2002-11-27 | 2004-05-27 | The Regents Of The University Of California | Transport of basic fibroblast growth factor across the blood brain barrier |
| US20070185044A1 (en) * | 2005-03-08 | 2007-08-09 | Dobie Kenneth W | Modulation of ace2 expression |
| EP1723962A1 (en) * | 2005-05-19 | 2006-11-22 | IMBA-Institut für Molekulare Biotechnologie GmbH | Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries |
| LT2691417T (lt) * | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| MX2014015557A (es) * | 2012-06-21 | 2015-02-24 | Univ Indiana Res & Tech Corp | Polipeptidos de fusion de region fc de polipeptido de ligando receptor de incretina y conjugados con función efectora fc alterada. |
| CA2902841A1 (en) * | 2013-03-13 | 2014-10-02 | Creatics Llc | Methods and compositions for detecting pancreatic cancer |
| AR103268A1 (es) * | 2014-12-23 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra tigit |
| US20220002699A1 (en) * | 2020-03-07 | 2022-01-06 | Planet Biotechnology, Inc. | ACE2-Fc FUSION PROTEINS FOR SARS-COV-2 MITIGATION |
| CN113444710A (zh) * | 2020-03-25 | 2021-09-28 | 上海英脉德医疗科技有限公司 | ACE2-Fc融合蛋白及其用途 |
| WO2021202427A2 (en) * | 2020-03-29 | 2021-10-07 | R-Pharm Overseas, Inc. | Ace2-derived composition and use thereof |
| US20210363512A1 (en) * | 2020-05-22 | 2021-11-25 | Formycon Ag | ACE2 fusion proteins and uses thereof |
-
2021
- 2021-07-20 EP EP21752830.6A patent/EP4182458A2/en active Pending
- 2021-07-20 JP JP2023504023A patent/JP2023535695A/ja active Pending
- 2021-07-20 US US18/016,209 patent/US20230272359A1/en active Pending
- 2021-07-20 CN CN202180058122.4A patent/CN116171324A/zh active Pending
- 2021-07-20 WO PCT/US2021/042372 patent/WO2022020353A2/en not_active Ceased
- 2021-07-20 CA CA3189732A patent/CA3189732A1/en active Pending
- 2021-07-20 AU AU2021312238A patent/AU2021312238A1/en active Pending
- 2021-07-20 KR KR1020237003077A patent/KR20230058045A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110234355B (zh) | 单体人IgG1 Fc和双特异性抗体 | |
| WO2018028635A1 (zh) | 一种寨卡病毒人源单克隆抗体及其应用 | |
| NZ719092A (en) | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof | |
| WO2021052349A1 (zh) | Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 | |
| WO2016179212A1 (en) | Antibody therapeutics against filovirus infections and uses thereof | |
| AU2021262794A1 (en) | Anti-CD26 proteins and uses thereof | |
| US20250009854A1 (en) | Antiviral Agent Comprising a Cellular Entry Receptor and Fc Region Component | |
| CA3170338A1 (en) | Engineered anti-her2 bispecific proteins | |
| US20240010695A1 (en) | Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function | |
| KR20230141839A (ko) | 전하쌍을 갖는 이중 특이성 항체 및 이의 용도 | |
| US20230293648A1 (en) | Stabilized ace2 variant, ace2-fc fusion protein using same, and method for preventing or treating covid-19 | |
| JP2024544531A (ja) | 位置429に変異を有するfc領域成分を含む免疫療法タンパク質 | |
| CA3218571A1 (en) | Methods of screening and expression of disulfide-bonded binding polypeptides | |
| CA3172941A1 (en) | Sialidase-pd-1-antibody fusion proteins and methods of use thereof | |
| WO2013013029A1 (en) | Anti-clta4, anti-glut2 protein for the treatment of type 1 diabetes | |
| KR102725210B1 (ko) | 안정화된 Ace2 변이체, 이를 이용한 Ace2-Fc 융합단백질 및 COVID-19 예방 또는 치료용 약학 조성물 | |
| CN120112558A (zh) | 治疗慢性病毒感染的含cd8抗原结合分子的融合物 | |
| CN113817051B (zh) | 一种抗SARS-CoV-2的单克隆抗体1B6 | |
| EP3366704A1 (en) | Antibodies specific for mmp1/hla-a2 complex | |
| WO2023288078A1 (en) | Coronavirus antibodies and uses thereof | |
| CN113817050B (zh) | 一种抗SARS-CoV-2的单克隆抗体1H8 | |
| WO2026072786A1 (en) | Clostridium difficile binary toxin neutralizing antibodies | |
| CN121843714A (zh) | Tl1a结合抗体及使用方法 | |
| US20240376195A1 (en) | ANTI-NKp30 ANTIBODIES AND METHODS OF USE | |
| EP4671273A1 (en) | INTERLEUKIN 21 PROXIMITY ACTIVATED |